Get the Stockscreener App
2.57
0.00%
0.00
After Hours:
2.56
-0.010
-0.39%
Repare Therapeutics Inc stock is traded at $2.57, with a volume of 1.43M.
It is up +0.00% in the last 24 hours and up +16.03% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
See More
Previous Close:
$2.57
Open:
$2.57
24h Volume:
1.43M
Relative Volume:
1.74
Market Cap:
$110.79M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-1.1525
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
-0.39%
1M Performance:
+16.03%
6M Performance:
+78.47%
1Y Performance:
+86.23%
1-Day Range:
$2.55
$2.58
1-Week Range:
$2.55
$2.655
52-Week Range:
$0.89
$2.66
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
2.57 | 110.79M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug - MSN
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Nigeria
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
Repare’s Sale Sparks Concerns: Time to Sell? - StocksToTrade
Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX) - MarketBeat
Gilead Sciences Acquires Polθ ATPase Inhibitor RP-3467 for $30 Million - El-Balad.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Repare Therapeutics Faces Scrutiny Amid Sale Deal - timothysykes.com
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead - GuruFocus
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln - Nasdaq
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Bluefield Daily Telegraph
Order Flow Trends Show Accumulation in Graphite India LimitedPortfolio Risk Assessment & Free Powerful Profit Generation - earlytimes.in
Will Repare Therapeutics Inc. stock gain from lower inflationEarnings Surprise Analysis & Our Picks = Your Future Gains - bollywoodhelpline.com
Can Repare Therapeutics Inc. stock double in next 5 yearsJuly 2025 Weekly Recap & Daily Oversold Bounce Ideas - Улправда
Repare Therapeutics Announces Resignation of Chief Scientific Officer - TradingView — Track All Markets
Repare Therapeutics Inc. Announces Resignation Ofmichael Zinda as Chief Scientific Officer, Effective December 31, 2025 - marketscreener.com
Why Repare Therapeutics Inc. stock is considered a top pickWeekly Market Report & Stepwise Swing Trade Plans - DonanımHaber
XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR - MSN
Why Repare Therapeutics Inc. stock is in analyst buy zone2025 Geopolitical Influence & Safe Swing Trade Setups - Улправда
Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights - Sahm
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-RPTX, FRGE, CSGS, FIZN - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN - Benzinga
Repare Therapeutics Inc. (NASDAQ:RPTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Repare Therapeutics announces shareholder meeting for acquisition approval - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN - Sahm
Repare Therapeutics Announces Shareholder Meeting for Acquisition Approval - TipRanks
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Repare Therapeutics (RPTX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Levels Update: Will Repare Therapeutics Inc. stock gain from lower inflation2025 AllTime Highs & Expert Verified Movement Alerts - moha.gov.vn
Will Repare Therapeutics Inc. stock deliver strong dividend growth2025 Momentum Check & Risk Adjusted Swing Trade Ideas - Newser
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerRPTX, AXTA, WTG and SEMR - Eastern Progress
Risk Report: Why Repare Therapeutics Inc. stock is in analyst buy zone2025 Price Momentum & Daily Price Action Insights - moha.gov.vn
Halper Sadeh LLC Encourages THS, RPTX, AXTA Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repare Therapeutics Inc Stock (RPTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 12 '25 |
Sale |
1.14 |
5,611 |
6,397 |
80,297 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 12 '25 |
Sale |
1.14 |
6,884 |
7,848 |
54,786 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Mar 12 '25 |
Sale |
1.14 |
21,179 |
24,144 |
124,394 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):